DNA Script

DNA Script

Private
Paris, Île-de-FranceHealthcare & Life Scienceshttps://www.dnascript.com

Last Round

Series C

Jan 4, 2022

Total Funding Raised

$324.55M

Momentum Score

50 /100

Company Overview

DNA Script is a biotechnology company that specializes in DNA printer technology for the rapid and high-quality production of synthetic nucleic acids used in genomics and molecular biology applications.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

enzymatic DNA synthesisEDSDNA printerDNA printingon-demand DNA synthesisbenchtop DNA printerDNA synthesizeroligo synthesisin-house DNA synthesissynthetic biology toolslife sciences instrumentationhardware and consumables modelrazor and blade modellab automationRNA vaccine production

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DNA Script Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

DNA Script Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CJan 4, 2022
GrantApr 27, 2021
GrantMar 2, 2021
Series BJul 29, 2020
GrantJul 10, 2018
Grant
Apr 4, 2018

Key People

Founding team and executive leadership

Xavier Godron

Co-founder CTO

Founding Team

Marc Montserrat

Chief Executive Officer

Executive Team

DNA Script Investors

Notable investors and investment history

InvestorRounds
Farallon Capital ManagementSeries C
EQT Life SciencesSeries B, Series C
Idinvest PartnersSeed, Series B, Series A
European CommissionGrant
M VenturesSeries C, Series A, Series B
Columbia Threadneedle InvestmentsSeries C
BpifranceGrant, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 17, 2026

    Agreement signed with BioStream Co. for South Korea distribution.

  • Mar 17, 2026

    Partnered with Bio-Medical Science Co. to expand SYNTAX platform access in Japan.

DNA Script Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

DNA Script Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DNA Script's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis, Île-de-France
Employee Range141
Year Founded2014
Last FundingJan 4, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.